Korean J Physiol Pharmacol.  2003 Apr;7(2):111-117.

Selective Cytotoxicity of Novel Platinum (II) Coordination Complexes on Human Bladder Cancer Cell-Lines and Normal Kidney Cells

Affiliations
  • 1Department of Pharmacochemistry, College of Pharmacy, School of Medicine, Kyung Hee University, Seoul 130-701, Korea.
  • 2Department of Pharmacology, School of Medicine, Kyung Hee University, Seoul 130-701, Korea. jungjc@khu.ac.kr

Abstract

Cisplatin is often effective in cancer treatment, but its clinical use is limited because of its nephrotoxicity. We have synthesized new platinum (II) coordination complexes (PC-1 & PC-2) containing trans-l and cis-1, 2-diaminocyclohexane (DACH) as carrier ligands and L-3 -phenyllactic acid (PLA) as a leaving group with the aim of reducing nephrotoxicity but maintaining its anticancer activity. In this study, new platinum (II) complex compounds were evaluated for selective cytotoxicity on cancer cell-lines and normal kidney cells. The new platinum complexes have demonstrated high efficacy in the cytotoxicity against human bladder carcinoma cell-lines (T-24/HT-1376). The cytotoxicity of these compounds against rabbit proximal renal tubular cells and human renal cortical tissues, was determined by MTT assay, the [3H]-thymidine uptake and glucose consumption test, and found to be quite less than those of cisplatin. Based on our results, these novel platinum compounds appear to be valuable lead compounds with high efficacy and low nephrotoxicity.

Keyword

Selective cytotoxicity; Platinum (II) complex; Human bladder carcinoma cells; Normal kidney cells

MeSH Terms

Cisplatin
Coordination Complexes*
Glucose
Humans*
Kidney*
Ligands
Platinum Compounds
Platinum*
Urinary Bladder Neoplasms*
Urinary Bladder*
Cisplatin
Coordination Complexes
Glucose
Ligands
Platinum
Platinum Compounds
Full Text Links
  • KJPP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr